Table 1: Study characteristics following pretherapeutic allocation.

Variable

RPVE

Mean, (SD), resp.%

EBRT

Mean, (SD), resp.%

P

Study participants

493

249

 

Age

66.70 (6.52)

72.55 (6.56)

< 0.0001

Proportion positive biopsies

0.40 (0.27)

0.36 (0.14)

0.4612

Gleason-score

5.79 (1.61)

6,68 (1.14)

< 0.0001

D’Amico-score

2.88 (1.44)

2.52 (1.43)

0.0004

Charlson Comorbidity -Index

0.68 (0.90)

1.14 (1.09)

< 0.0001

Prostate volume

42.95 (20.22)

30.07 (17.57)

< 0.0001

PSA

11.14 (12.64)

12.62 (15.20)

0.4339

Stage

cT1a-cT1c

cT2a-cT2b

 

60.8%

67.7%

 

39.2%

32.3%

 

< 0.0001

< 0.0001

cT2c

78.1%

21.9%

< 0.0001

cT3a-cT3b

35.7%

64.3%

< 0.0001